Prostate cancer (PCa) is the second most common cancer among men worldwide. Urinary, bowel, and sexual function, as well as hormonal symptoms and health-related quality of life (HRQoL), were prioritised by patients and professionals as part of a core outcome set for localised PCa regardless of treatment type.
Data evaluating the impact of positive vascular margins (PVMs) following surgical resection of non-metastatic renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus are lacking. To analyze the oncological impact of positive vascular margins following surgical resection of RCC with IVC tumor thrombus.
Both oncologic outcomes and patient-reported outcomes are pivotal in prostate cancer (PCa). However, it remains unknown if there is any association between these two outcomes. In this secondary analysis of a randomized controlled trial, we investigated the association of short-term changes in patient-reported outcome with long-term event-free survival (EFS) and metastasis-free survival (MFS) in localized […]
African men are disproportionately affected by prostate cancer (PCa). Given the increasing prevalence of obesity in Africa, and its association with aggressive PCa in other populations, we examined the relationship of overall and central obesity with risks of total and aggressive PCa among African men.
We examined the relationship between the tumour microenvironment and the clinical efficacy of neoadjuvant chemotherapy in patients with cT2-4aN0M0 bladder cancer using multiplex fluorescence immunohistochemistry.
To describe clinical, imaging, and histopathologic characteristics of inflammatory myofibroblastic tumor (IMT) of the urinary bladder and provide initial management and surveillance recommendations.
Alicia Morgans: Hi, my name is Alicia Morgans, and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute. I’m so excited to have here with me today a good friend and colleague, Dr. Tanya Dorff, who is a GU Medical Oncologist and Associate Professor of Medicine, as well as being the GU Section Chief at […]
Alicia Morgans: Hi. My name is Alicia Morgans, and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute. I’m so excited to have here with me today, a good friend and colleague, Dr. Oliver Sartor, who is a Professor of Medicine, and the Medical Director of the Tulane Cancer Center, as well as being the […]
KEYTRUDA Is Now Approved for the Adjuvant Treatment of Patients With RCC at Intermediate-High or High Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic LesionsKEYTRUDA Is the First Immunotherapy Approved for the Adjuvant Treatment of These Patients With RCC San Francisco, CA (UroToday.com) — Merck, known as MSD outside the United States […]
One of the main issues in testicular germ cell tumors (TGCTs) management is to reduce the necessary amount of treatment to achieve cure. Excess treatment burden may arise from late diagnosis of the primary as well as from false positive or negative staging results.
